A Multicentre Phase II Study of AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs AZD-1775 (Primary) ; Carboplatin; Gemcitabine; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 14 Nov 2017 Planned End Date changed from 30 Apr 2018 to 31 May 2018.
- 14 Nov 2017 Planned primary completion date changed from 30 Apr 2018 to 2 Mar 2018.
- 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.